Search clinical trials for: MK-1084

Total 2069 results

Dana-Farber Cancer Institute
Kazia Therapeutics Limited

Recruiting

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Metastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland Pheochromocytoma

United States
Otonomy, Inc.

Terminated

Study of OTO-104 in Subjects With Unilateral Meniere's Disease (AVERTS-2)

Meniere's Disease

United States
Otonomy, Inc.

Completed

Study of OTO-104 in Subjects With Unilateral Meniere's Disease (AVERTS-1)

Meniere's Disease

United States
Otonomy, Inc.

Completed

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Meniere's Disease

United Kingdom
University of Texas Southwestern Medical Center
Stanley Medical Research Institute; ACADIA Pharmaceuticals Inc.

Completed

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics (ACP-104)

Schizophrenia

United States
Second Affiliated Hospital, School of Medicine,...

Completed

Comparison of Picosecond Lasers vs. Ablative Fractional Er:YAG Lasers in Treating Atrophic Scar

Acne | Atrophic Scar

China
HiberCell, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Active, not recruiting

ABEMA Alone or in COMBO With MK-6482

Clear Cell Renal Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Melanoma | Carcinoma, Non-Small-Cell Lung

India
Lynn Feun, MD
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Malignant Pleural Mesothelioma

United States
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Anesthesia, General
RWTH Aachen University

Completed

Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients

CKD 5D, Hemodialysis

Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)

Renal Cell Carcinoma

Poland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

Poland, Korea, Republic of, United States, Argentina, Australia, Canada, Colombia, France, Germany, Guatemala, Israel, Italy, Japan, Latvia, Mexico, Peru, Puerto Rico, Romania, South Africa, Spain, Sweden, Turkey, Ukraine
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Advanced Melanoma

Canada, United States, Australia, Spain, Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Small Cell Lung Cancer

Poland, Russian Federation, United States, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease
Merck Sharp & Dohme LLC
PPD, Part of Thermo Fisher Scientific

Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Ulcerative Colitis

United States, Israel, Japan, Korea, Republic of, Switzerland, Chile, Dominican Republic, Canada, Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

End Stage Renal Disease | Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) (MOVe-AHEAD)

Coronavirus Disease (COVID-19)

United States, Argentina, Brazil, Bulgaria, Colombia, Dominican Republic, Egypt, France, Guatemala, Hungary, Japan, Kenya, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, South Africa, Spain, Thailand, Turkey, Ukraine
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Ovarian Neoplasms
Affimed GmbH
Merck Sharp & Dohme LLC; The Leukemia and Lymphoma Society

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Spain
Kowa Research Institute, Inc.

Withdrawn

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Jazz Pharmaceuticals

Recruiting

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Parkinson Disease | Tremor

United States, Spain, Germany, Poland
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1)

Castration-resistant Prostate Cancer

United Kingdom
Organon and Co

Completed

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

Hypogonadotropic Hypogonadism

Brazil, Denmark, Italy, Mexico, Russian Federation, South Africa
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Cancer, Solid Tumor
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Anesthesia, General
Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
Takeda

Completed

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Crohn's Disease

Belgium, Israel, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Hungary, Serbia, Bulgaria, Canada, Germany, Italy, Poland, Slovakia, Czechia, Mexico, Romania, Brazil, Estonia, United States, Bosnia and Herzegovina and more
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
National Institute of Allergy and Infectious Diseases...

Recruiting

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)

Zika Virus

United States
Nectin Therapeutics Ltd
Merck Sharp & Dohme LLC

Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Cancer | Metastatic Cancer | Advanced Solid Tumor | Tumor, Solid | Locally Advanced Solid Tumor

United States, Israel
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

Insomnia

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation; Dracen Pharmaceuticals, Inc.

Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Fibrolamellar Hepatocellular Carcinoma

United States
King's College London
Washington Red Raspberries Commission

Recruiting

Gut Microbial Metabolism of Polyphenols and Cardiovascular Health (StratiPol) (Stratification Study) (StratiPol)

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Malaysia, Mexico, New Zealand, Norway, Peru, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Thailand, Tu... and more

Search clinical trials for: MK-1084

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations